Dyslipidemia, Metabolic Syndrome
Conditions
Keywords
Metabolic Syndrome, Dyslipaemia
Brief summary
The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.
Interventions
DRUGRosuvastatin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
45 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent * males aged 45-65 * insulin resistance * central obesity * LDL-C \<6 mmol/L * plasma triglycerides \>=1.7 and ≤5.5 mmol/L * HDL-C ≤1.2 mmol/L.
Exclusion criteria
* total cholesterol \>7mmol/L * pre-existing cardiovascular disease, diabetes, proteinuria or renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the effect of treatment with rosuvastatin on: | — |
| - cholesterol esterification by measuring plasma lecithin:cholesterol acyl transferase concentration and capacity to esterify cholesterol, one of the stops in RCT. | — |
| - plasma concentration of cholesterol ester transfer protein and capacity to transfer cholesterol from HDL-C to apoB-containing lipoproteins, one of the steps in RCT. | — |
| - plasma concentration of preβ1-HDL. | — |
| - plasma concentration of LDL cholesterol, HDL-C and apoA-1. | — |
Countries
Australia
Outcome results
None listed